Anti-obesity Drugs Market Size to Hit USD 104.9 Billion by 2035 | Exclusive Report by Roots Analysis
The anti-obesity drugs market, valued at USD 12.8 billion in 2024, is projected to grow to USD 19.6 billion in 2025 and USD 104.9 billion by 2035, representing a CAGR of 18.3% during the forecast period.
Link: https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html
Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues. These medications provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and potentially lower healthcare costs by preventing complications associated with obesity. Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.
Anti-obesity Drugs Market Segments
Based on the type of molecule, the market is segmented into biologics and small molecules
§ The small molecules segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
§ The biologics segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 23.8%, during the forecast period.
Based on the active compound used, the market is segmented into tirzepatide, semaglutide, retatrutide, survodutide, cagrilintide and semaglutide, orforglipron, liraglutide, other active compounds
§ The semaglutide segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
§ The tirzepatide segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 18.3%, during the forecast period.
Based on the mechanism of action, the market is segmented into GLP-1 agonists / GIP agonists, GLP-1 agonists / GCGR agonists, GLP-1 agonists, GLP-1 agonists / Amylin analogues, GLP-1 / GCGR / GIP agonists and other mechanisms of action
§ The GLP-1 agonists segment is likely to capture the largest revenue share of 65% in the anti-obesity drugs market in 2024.
§ The GLP-1 agonists / GIP agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.
Based on the type of agonist, the market is segmented into single-agonists, dual-agonists and tri-agonists
§ The single-agonists segment is likely to capture the largest revenue share of around 70% in the anti-obesity drugs market in 2024.
§ The dual-agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 25.7%, during the forecast period.
Based on the action pathway, the market is segmented into centrally acting, peripherally acting, centrally acting and peripherally acting drugs
§ The centrally acting drugs segment is likely to capture the largest revenue share of around 85% in the anti-obesity drugs market in 2024.
§ The centrally acting drugs segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.6%, during the forecast period.
Based on the route of administration, the market is segmented into oral and parenteral route of administration
§ The segment for parenteral route of administration is likely to capture the largest revenue share of more than 95% in the anti-obesity drugs market in 2024.
§ The segment for oral route of administration is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 40.6%, during the forecast period.
Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific and Latin America
§ North America is likely to dominate the anti-obesity drugs market, by capturing the largest revenue share of nearly 70%, in 2024.
§ In Asia-Pacific, the anti-obesity drugs market is likely to demonstrate considerable growth with a relatively higher CAGR (~40%) during the forecast period.
Anti-obesity Drugs Market Regional Outlook
Based on the geographical regions, the anti-obesity drugs market can be segmented into four major regions, North America, Europe, Asia-Pacific and Latin America. Led by the US, North America is anticipated to capture the majority share of the anti-obesity drugs market in 2024. Further, the weight loss industry in Asia-Pacific is accounted to be the fastest-growing segment of the market. This is primarily due to the increased awareness and acceptance of obesity as a chronic disease in the region.
Key Market Players
§ Adocia
§ AstraZeneca
§ Boehringer Ingelheim
§ CinFina Pharma
§ Eli Lilly
§ Gmax Biopharma
§ Hanmi Pharm
§ Jiangsu Hengrui Pharmaceuticals
§ Kallyope
§ Novo Nordisk
§ PegBio
§ Pfizer
§ QL Biopharm
§ Regeneron
§ Roche
§ Sciwind Biosciences
§ Viking Therapeutics
§ Zealand Pharma
Anti-obesity Drugs Market Segments
Anti-obesity Drugs Market, by Type of Molecule
§ Biologics
§ Small Molecules
Anti-obesity Drugs Market, by Active Compound Used
§ Tirzepatide
§ Semaglutide
§ Retatrutide
§ Survodutide
§
